, Volume 69, Issue 17, pp 2393–2414 | Cite as


More Than a Decade of Experience
  • Henry R. Black
  • Jacqueline Bailey
  • Dion Zappe
  • Rita Samuel
Review Article


Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding of angiotensin II to the angiotensin II type 1 receptor. The efficacy, tolerability and safety of valsartan have been demonstrated in large-scale studies in hypertension, heart failure (HF) and post-myocardial infarction (MI). This review focuses on what was learned from the valsartan clinical research programme and other comparative trials published from 1997 to the present.

Many studies have demonstrated the efficacy of valsartan in lowering blood pressure (BP) in a variety of patient populations (including elderly, women, children, obese patients, patients with diabetes mellitus, patients with chronic kidney disease [CKD], patients at high risk of cardiovascular [CV] disease, African Americans, Hispanic Americans and Asians) and in improving outcomes in CV disease and CKD. In hypertension, valsartan exhibits dose-dependent efficacy in reducing both systolic and diastolic BP over the once-daily dose range of 80–320 mg; doses as high as 640 mg/day have been studied and found to be efficacious and safe. BP control can be enhanced with a more consistent 24-hour BP-lowering profile by using single-pill, fixed-dose combination therapy with valsartan plus hydrochlorothiazide (HCTZ).

The cardioprotective benefits of valsartan have been demonstrated in large-scale outcome trials and include significant reductions in CV morbidity and mortality in HF, following MI, and in patients with co-morbid hypertension and coronary artery disease and/or HF; reductions in HF hospitalizations; and reductions in the incidence of stroke. The magnitude of these effects is comparable with that demonstrated with angiotensin-converting enzyme (ACE) inhibitors; however, valsartan has a more favourable tolerability profile, with a significantly lower incidence of cough and only rare reports of angio-oedema, both class effects of ACE inhibitor use. Consistent with its angiotensin receptor-blocking effects, valsartan also reduces circulating levels of biochemical markers that are associated with angiotensin II-mediated endothelial dysfunction and CV risk (e.g. high-sensitivity C-reactive protein or oxidized low-density lipoprotein).

Improvements in CKD with valsartan include statistically and clinically meaningful reductions in urinary albumin and protein excretion in patients with type 2 diabetes and in nondiabetic patients with CKD. In short-term studies, valsartan has improved or stabilized various indices of metabolic function in at-risk patients, including those with co-morbid hypertension, obesity and/or metabolic syndrome. Because of this, valsartan is being prospectively investigated for its ability to reduce the incidence of new-onset diabetes and provide cardioprotection in patients with impaired glucose tolerance.

Valsartan and valsartan/HCTZ are well tolerated. In clinical trials, adverse events during valsartan treatment were similar to those occurring with placebo. The combination of valsartan/HCTZ was better tolerated than HCTZ alone. Valsartan is administered once daily for hypertension; doses are usually taken upon awakening. In patients with HF or MI, valsartan is administered twice daily.



The preparation of this manuscript was made possible by funding from Novartis Pharmaceuticals Corporation. Dr Bailey prepared the first draft of the manuscript after discussions with the other authors and with input from all authors, each of whom reviewed and revised it critically for important intellectual content. All authors approved the final version that is submitted for publication. The authors confirm that this review is an accurate representation of the literature.

Dr Black has received consultant fees from, and has served on advisory panels for, Novartis Pharmaceuticals Corporation, Boehringer-Ingelheim Pharmaceuticals Inc., Daiichi-Sankyo, sanofi-aventis, Bristol-Myers Squibb, and Merck and Co., Inc. He is also a consultant for Intercure, Ligand, XOMA and CVRx. Dr Bailey is an employee of Oxford PharmaGenesis Inc. Drs Zappe and Samuel are employees of Novartis.


  1. 1.
    Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens 2002 May; 16 Suppl. 2: S2–6PubMedGoogle Scholar
  2. 2.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42: 1206–52PubMedGoogle Scholar
  3. 3.
    KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007 Feb; 49 (2 Suppl. 2): S12–54Google Scholar
  4. 4.
    Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 2008 Jun 28; 371: 2219–21PubMedGoogle Scholar
  5. 5.
    Diovan (valsartan) tablets [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2008 Dec [online]. Available from URL: http://www.pharma.us.novartis.com/products/name/diovan.jsp [Accessed 2009 Aug 18]
  6. 6.
    Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997 Aug; 54: 299–311PubMedGoogle Scholar
  7. 7.
    Flesch G, Müller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997; 52: 115–20PubMedGoogle Scholar
  8. 8.
    Lacourciére Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005 Jul; 27: 1013–21PubMedGoogle Scholar
  9. 9.
    Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl. 2003 May; 1: 36–43PubMedGoogle Scholar
  10. 10.
    Calhoun DA, Glazer RD, Pettyjohn FS, et al. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin 2008 Aug; 24: 2303–11PubMedGoogle Scholar
  11. 11.
    Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007 Jan; 29: 61–73PubMedGoogle Scholar
  12. 12.
    Cifkova R, Peleska J, Hradec J, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998 Aug; 12: 563–7PubMedGoogle Scholar
  13. 13.
    Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive post-menopausal women. Am J Hypertens 2004 Jan; 17: 77–81PubMedGoogle Scholar
  14. 14.
    Mallion JM, Boutelant S, Chabaux P, et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit 1997 Aug; 2: 179–84PubMedGoogle Scholar
  15. 15.
    Fogari R, Zoppi A, Carretta R, et al. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J Hypertens 2002 May; 20: 1007–14PubMedGoogle Scholar
  16. 16.
    Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004 Jun; 26: 855–65PubMedGoogle Scholar
  17. 17.
    Elliott WJ, Calhoun DA, DeLucca PT, et al. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001 Aug; 23: 1166–79PubMedGoogle Scholar
  18. 18.
    Calvo C, Hermida RC, Ayala DE, et al. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004 Apr; 22: 837–46PubMedGoogle Scholar
  19. 19.
    Destro M, Scabrosetti R, Vanasia A, et al. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv Ther 2005 Jan; 22: 32–43PubMedGoogle Scholar
  20. 20.
    Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003 Nov; 25: 2765–80PubMedGoogle Scholar
  21. 21.
    Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005 May; 27: 578–87PubMedGoogle Scholar
  22. 22.
    Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007 Jan; 49: 69–75PubMedGoogle Scholar
  23. 23.
    White WB, Calhoun DA, Samuel R, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich) 2008 Jun; 10: 450–8Google Scholar
  24. 24.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363: 2022–31PubMedGoogle Scholar
  25. 25.
    Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005 Sep 10; 366: 907–13PubMedGoogle Scholar
  26. 26.
    Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007 Jul; 20: 807–15PubMedGoogle Scholar
  27. 27.
    Jamerson KA, Zappe DH, Collins L, et al. The time to blood pressure (BP) control by initiating antihypertensive therapy with a higher dose of valsartan (160mg) or valsartan/hydrochlorothiazide compared to low-dose valsartan (80 mg) in the treatment of hypertension: the VELOCITY study [abstract no. P-400]. J Clin Hypertens 2007; 9 (5 Suppl. A): A166Google Scholar
  28. 28.
    Kolloch RE, Ferber P. A randomized, double-blind study to compare a valsartan-based vs an amlodipine-based treatment algorithm in achieving blood pressure control: the PROMPT study [abstract]. J Clin Hypertens 2008 Jun; 10: 509Google Scholar
  29. 29.
    Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978 Apr 15; 1: 795–7PubMedGoogle Scholar
  30. 30.
    Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985 Nov 21; 313: 1315–22PubMedGoogle Scholar
  31. 31.
    Willich SN, Levy D, Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987 Oct 1; 60: 801–6PubMedGoogle Scholar
  32. 32.
    Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003 Mar 18; 107: 1401–6PubMedGoogle Scholar
  33. 33.
    Izzedine H, Launay-Vacher V, Deray G. Abnormal blood pressure circadian rhythm: a target organ damage? Int J Cardiol 2006 Mar 8; 107: 343–9PubMedGoogle Scholar
  34. 34.
    Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007 Oct 6; 370: 1219–29PubMedGoogle Scholar
  35. 35.
    Pedersen OL, Mancia G, Pickering T, et al. Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. J Hypertens 2007 Mar; 25: 707–12PubMedGoogle Scholar
  36. 36.
    Myers MG. Methods for evaluating the duration of action of once-daily antihypertensive therapy. Blood Press Monit 2003 Aug; 8: 161–3PubMedGoogle Scholar
  37. 37.
    Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003 Sep; 42: 283–90PubMedGoogle Scholar
  38. 38.
    Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007 Jul 21; 370: 221–9PubMedGoogle Scholar
  39. 39.
    Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997 May; 19: 447–58PubMedGoogle Scholar
  40. 40.
    Franco RJ, Goldflus S, McQuitty M, et al. Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. Blood Press Suppl 2003 Dec; 2: 41–7PubMedGoogle Scholar
  41. 41.
    Ruilope LM, Heintz D, Brandao AA, et al. 24-Hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study. Blood Press Monit 2005 Apr; 10: 85–91PubMedGoogle Scholar
  42. 42.
    Weir MR, Ferdinand KC, Flack JM, et al. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 2005 Sep; 46: 508–13PubMedGoogle Scholar
  43. 43.
    Hermida RC, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005 Oct; 23: 1913–22PubMedGoogle Scholar
  44. 44.
    Lasko BH, Laplante A, Hébert D, et al. Canadian valsartan study in patients with mild-to-moderate hypertension. Blood Press Monit 2001 Apr; 6: 91–9PubMedGoogle Scholar
  45. 45.
    Monterroso VH, Rodriguez Chavez V, Carbajal ET, et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan: Losartan Trial Investigators. Adv Ther 2000 Mar; 17: 117–31PubMedGoogle Scholar
  46. 46.
    Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006 Sep; 23: 680–95PubMedGoogle Scholar
  47. 47.
    White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004 Apr; 17: 347–53PubMedGoogle Scholar
  48. 48.
    Palatini P, Mugellini A, Spagnuolo V, et al. Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-Syst study). Blood Press Monit 2004 Apr; 9: 91–7PubMedGoogle Scholar
  49. 49.
    Lacourciére Y, Wright Jr JT, Samuel R, et al. Is the combination of valsartan/hydrochlorothiazide regimen more effective, compared to conventional treatment with amlodipine and hydrochlorothiazide, in lowering ambulatory blood pressure (BP) in patients with stage 2 hypertension? The EVALUATE study [poster]. American Society for Hypertension, 23rd Annual Scientific Meeting and Exposition; 2008 May 14–17; New Orleans (LA)Google Scholar
  50. 50.
    White WB. Ambulatory blood pressure monitoring: dippers compared with non-dippers. Blood Press Monit 2000; 5 Suppl. 1: S17–23PubMedGoogle Scholar
  51. 51.
    Parati G, Omboni S, Rizzoni D, et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998 Nov; 16: 1685–91PubMedGoogle Scholar
  52. 52.
    Fogari R, Mugellini A, Zoppi A, et al. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res Clin Exp 2002; 63: 1–14Google Scholar
  53. 53.
    Hermida RC, Ayala DE, Khder Y, et al. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther 2008 Jan; 30: 108–20PubMedGoogle Scholar
  54. 54.
    Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged ≥65 years with systolic hypertension. Clin Ther 2000 Aug; 22: 961–9PubMedGoogle Scholar
  55. 55.
    Black HR, Levy DG, Crikelair N, et al. Predicting age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertens 2008; 2: 476–83PubMedGoogle Scholar
  56. 56.
    Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005 Mar; 28: 209–14PubMedGoogle Scholar
  57. 57.
    Fogari R, Derosa G, Mugellini A, et al. Effect of valsartan on adiponectine, leptin and resistine in hypertensive obese patients [abstract no. P-521]. Am J Hypertens 2005 May; 18 (5 Pt 2): 196A–7AGoogle Scholar
  58. 58.
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25: 1105–87PubMedGoogle Scholar
  59. 59.
    Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003 Mar; 14: 641–7PubMedGoogle Scholar
  60. 60.
    Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001 Jul 25; 286: 421–6PubMedGoogle Scholar
  61. 61.
    Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007 Sep; 25: 1921–6PubMedGoogle Scholar
  62. 62.
    Zappe DH, Sowers JR, Hsueh WA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008 Dec; 10: 894–903Google Scholar
  63. 63.
    Raij L, Sowers JR, Jialal I, et al. Metabolic effects of combination angiotensin receptor blockade/hydrochlorothiazide in pre-diabetic, obese, hypertensive patients [poster]. 18th Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension; 2008 Jun 14–19; BerlinGoogle Scholar
  64. 64.
    Prabowo P, Arwanto A, Soemantri D, et al. A comparison of valsartan and captopril in patients with essential hypertension in Indonesia. Int J Clin Pract 1999 Jun; 53: 268–72PubMedGoogle Scholar
  65. 65.
    Lee CM, Lee YT, Lang MG, et al. A comparison of valsartan and captopril in Taiwanese patients with essential hypertension. Adv Ther 1999; 16: 39–48Google Scholar
  66. 66.
    Patel JK, Leaback R, on behalf of the POSATIV Investigators. Patients of Southern Asian descent treated with valsartan (POSATIV) study. Br J Cardiol 2002 Jun; 9: 351–4Google Scholar
  67. 67.
    Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005 Mar; 149: 548–57PubMedGoogle Scholar
  68. 68.
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 Dec 6; 345: 1667–75PubMedGoogle Scholar
  69. 69.
    Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002 Sep 4; 40: 970–5PubMedGoogle Scholar
  70. 70.
    Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002 Nov 5; 106: 2454–8PubMedGoogle Scholar
  71. 71.
    Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002 Oct 16; 40: 1414–21PubMedGoogle Scholar
  72. 72.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 Nov 13; 349: 1893–906PubMedGoogle Scholar
  73. 73.
    Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006 Sep; 48: 385–91PubMedGoogle Scholar
  74. 74.
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004 Jun 19; 363: 2049–51PubMedGoogle Scholar
  75. 75.
    Aksnes TA, Schmieder RE, Kjeldsen SE, et al. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 2008 Mar 1; 101: 634–8PubMedGoogle Scholar
  76. 76.
    Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008 Mar; 26: 403–11PubMedGoogle Scholar
  77. 77.
    Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 2008 Sep; 21: 1034–9PubMedGoogle Scholar
  78. 78.
    Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2008 Mar; 51: 217–22PubMedGoogle Scholar
  79. 79.
    GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation [published erratum appeared in N Engl J Med 2009 May 28; 360 (22): 2379]. N Engl J Med 2009 Apr 16; 360(16): 1606–17PubMedGoogle Scholar
  80. 80.
    Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006 Jul; 48: 73–9PubMedGoogle Scholar
  81. 81.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov 20; 359: 2195–207PubMedGoogle Scholar
  82. 82.
    Sampson UK, Pfeffer MA, McMurray JJ, et al. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. Eur Heart J 2007 Mar; 28: 685–91PubMedGoogle Scholar
  83. 83.
    McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006 Feb 21; 47: 726–33PubMedGoogle Scholar
  84. 84.
    Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004 Feb; 59: 863–8PubMedGoogle Scholar
  85. 85.
    Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106: 672–8PubMedGoogle Scholar
  86. 86.
    Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007 Jun; 30: 1581–3PubMedGoogle Scholar
  87. 87.
    Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008 Oct; 23: 3174–83PubMedGoogle Scholar
  88. 88.
    Ishimitsu T, Kameda T, Akashiba A, et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005 Nov; 28: 865–70PubMedGoogle Scholar
  89. 89.
    Durmus A, Dogan E, Erkoc R, et al. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients. Int J Clin Pract 2005 Sep; 59: 1001–4PubMedGoogle Scholar
  90. 90.
    Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004 Jun; 43: 1056–64PubMedGoogle Scholar
  91. 91.
    Muirhead N, House A, Hollomby DJ, et al. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc 2003 Nov; 35: 2412–4PubMedGoogle Scholar
  92. 92.
    Top C, Cingözbay BY, Terekeci H, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002 Jan; 30: 15–20PubMedGoogle Scholar
  93. 93.
    Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001 Jul; 29: 270–9PubMedGoogle Scholar
  94. 94.
    Yilmaz MI, Sonmez A, Caglar K, et al. Effect of anti-hypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007 Apr; 12: 147–53Google Scholar
  95. 95.
    Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006 Jul; 24: 1405–12PubMedGoogle Scholar
  96. 96.
    Weycker D, Edelsberg J, Vincze G, et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens 2007 May; 21: 374–80PubMedGoogle Scholar
  97. 97.
    Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008 Apr 21; 51: 1617–23PubMedGoogle Scholar
  98. 98.
    Aksnes TA, Kjeldsen SE, Rostrup M, et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007 Sep; 50: 467–73PubMedGoogle Scholar
  99. 99.
    Califf RM, Boolell M, Haffner SM, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 2008 Oct; 156: 623–32PubMedGoogle Scholar
  100. 100.
    Diovan HCT (valsartan and hydrochlorothiazide) tablets [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2008 JulGoogle Scholar
  101. 101.
    Malacco E, Piazza S, Scandiani L, et al. Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Adv Ther 2004 May; 21: 149–61PubMedGoogle Scholar
  102. 102.
    Weir MR, Crikelair N, Levy D, et al. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007 Feb; 9: 103–12Google Scholar
  103. 103.
    Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther 2004 Apr; 26: 460–72PubMedGoogle Scholar
  104. 104.
    Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997 Sep; 62: 272–8PubMedGoogle Scholar
  105. 105.
    Prasad PP, Yeh CM, Gurrieri P, et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol 2002 Nov; 40: 801–7PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Henry R. Black
    • 1
  • Jacqueline Bailey
    • 2
  • Dion Zappe
    • 3
  • Rita Samuel
    • 3
  1. 1.New York University Center for the Prevention of Cardiovascular DiseaseNew York University School of MedicineNew YorkUSA
  2. 2.Oxford PharmaGenesis Inc.NewtownUSA
  3. 3.Novartis Pharmaceuticals CorporationEast HanoverUSA

Personalised recommendations